Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: A preliminary report of two cases

Antiviral Therapy

Volumn 20, Issue 1, 2015, Pages 87-91

  Khalid, Mohammed ^a   Al Rabiah, Fahad ^a   Khan, Basha ^a   Al Mobeireek, Abdullah ^a   Butt, Taimur S ^a   Al Mutairy, Eid ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME; METHYLPREDNISOLONE; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CASE REPORT; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; CORONAVIRUS INFECTION; DYSPNEA; FEMALE; FEVER; HUMAN; INFECTION PREVENTION; LUNG INFILTRATE; MALE; MIDDLE AGED; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; NONINVASIVE VENTILATION; OPEN READING FRAME; OXYGEN THERAPY; PRIMARY PREVENTION; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPUTUM ANALYSIS; THORAX RADIOGRAPHY; UPPER RESPIRATORY TRACT INFECTION; VIRUS DETECTION; CORONAVIRUS INFECTIONS; DRUG EFFECTS; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; RADIOGRAPHY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; VIRAL LOAD;

EID: 84927749252     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2792     Document Type: Article

References (13)

1. Chan PK, Chan MC. Tracing the SARS coronavirus. J Thorac Dis 2013; 5 Suppl 2:S118-S121.
2. de Groot RJ, Baker SC, Baric RS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol 2013; 87:7790-7792.
3. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814-1820.
4. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). (Accessed 16 April 2014.) Available from http://www.who.int/csr/disease/coronavirus-infections/MERS-CoV-Update-20-Jan-2014.pdf
5. Guery B, van der Werf S. Coronavirus: need for a therapeutic approach. Lancet Infect Dis 2013; 13:726-727.
6. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013; 19:1313-1317.
7. Falzarano D, de Wit E, Martellaro C, et al. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep 2013; 3:1686.
8. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13:752-761.
9. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) - July 2013. (Accessed 9 May 2014.) Available from www.who.int/csr/disease/ coronavirus-infections/en/
10. Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369:407-416.
11. Gautret P, Benkouiten S, Salaheddine I, Parola P, Brouqui P. Preventive measures against MERS-CoV for Hajj pilgrims. Lancet Infect Dis 2013; 13:829-831.
12. Al-Tawfiq JA, Momattin H, Dip J, Memish ZA. Ribavirin and interferon in patients infected with the Middle East respiratory syndrome corona virus: an observational study. Int J Infect Dis 2014; 20:42-46.
13. Momattin H, Mohammed K, Zumia A, Memish ZA, Al-Tawfiq JA. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV) - possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis 2013; 17:e792-e798.